

Telefax Transmittal
Cover sheet

AKIMA-DTSV 0 9 MAR 2005


AKZO NOBEL29160 Intervet Lane
P.O. Box 318
Millsboro, DE 19966-0318
(302) 934-8051

March 8, 2005

3...pages including cover sheet.

PERSON TO:	COMPANY/DEPT TO:	FAX NUMBER:
------------	------------------	-------------

Office of Initial Patent
Examination's Filing Receipt
CorrectionsUSPTO
Art Unit: 1615

703-746-9195

PERSON FROM:	COMPANY/DEPT FROM:	FAX NUMBER:
--------------	--------------------	-------------

Diane Payne

Patent Department

302-934-4305

USSN: 10/502,444

Attorney Reference No.: O-2002.713 US

Re: Filing Receipt of February 22, 2005

Please accept the documents which follow in the above-identified application:

Request for Corrected Filing Receipt (1 page)

Filing Receipt of February 22, 2005 with noted corrections thereon (2 pages)




THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN PROPRIETARY INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT THE ADDRESSEE, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, NOTIFY US IMMEDIATELY BY TELEPHONE (COLLECT). THANK YOU.

Attorney Docket No.: 0-2002.713 US

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

BY: Date: 3-8-05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

KLOOSTERBOER, ET AL.

Serial Number: 10/502,444

Group Art Unit: 1615

Filed: August 19, 2004

Examiner: To be assigned

For: TIBLONE TREATMENT OF COMPLAINTS ASSOCIATED WITH THE
ADMINISTRATION OF DRUGS WHICH PREVENT THE SYNTHESIS OF
ENDOGENOUS ESTROGEN

REQUEST FOR CORRECTED FILING RECEIPT


Honorable Assistant Commissioner of Patents
Alexandria, VA 22313

March 8, 2004

Sir:

It is respectfully requested that the Filing Receipt for the above-identified application be corrected to reflect the accurate spelling of the last word in the title of the invention from ~~estrogen~~ to estrogen. The Filing Receipt has been corrected and is included with this submission.

Respectfully submitted,



Mark W. Milstead
Attorney for Applicants
Registration No. 45,825

Akzo Nobel Pharma Patent Department
P.O. Box 318
Millsboro, DE 19966
Tel: (302) 933-4395
Fax: (302) 934-4305



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL. NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/502,444	07/21/2004	1615	920	O-2002.713 US		7	1

31846
AKZO NOBEL PHARMA PATENT DEPARTMENT
PO BOX 318
MILLSBORO, DE 19966

CONFIRMATION NO. 4004

FILING RECEIPT

OC000000015221417

Date Mailed: 02/22/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

**Helenius Jan Kloosterboer, Oss, NETHERLANDS;
Nigel Bundred, Manchester, UNITED KINGDOM;**

Power of Attorney:

William Blackstone—29772
William Ramey III—44295
Mark Milstead—45825

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/00373 01/16/2003

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 02075235.8 01/22/2002

Projected Publication Date: 05/26/2005

Non-Publication Request: No

Early Publication Request: No

Title

Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous ~~estrogen~~ *estrogen*

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).